Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Allied BiotechROCO:1780 -1.76%77 EV-to-FCF is 12.60 as of Jul. 19, 2026, which is 47% below its 10-year median of 23.94. GuruFocus rates ROCO:1780 with a GF Score™ of 77/100 and a GF Value™ of NT$20.77 (Fairly Valued). The stock has 5 warning signs investors should review. Among 565 Drug Manufacturers companies, Allied Biotech ranks better than 70.44% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Allied Biotech's Enterprise Value is NT$2,312.0 Mil.
Allied Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$183.5 Mil. Therefore, Allied Biotech's EV-to-FCF for today is 12.60.
The historical rank and industry rank for Allied Biotech's EV-to-FCF or its related term are showing as below:
ROCO:1780'
s EV-to-FCF Range Over the Past 10 Years
Min: 7.7 Med: 23.94 Max: 122.65
Current: 12.6
During the past 13 years, the highest EV-to-FCF of Allied Biotech was 122.65. The lowest was 7.70. And the median was 23.94.
ROCO:1780's EV-to-FCF is ranked better than 70.44% of 565
companies
in the Drug Manufacturers industry
Industry Median: 20.96
vs ROCO:1780: 12.60
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Allied Biotech's PE Ratio (TTM) for today is calculated as:
Allied Biotech's share price for today is NT$22.30.
Allied Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.340.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Allied Biotech EV-to-FCF Related Terms
Allied Biotech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Allied Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Allied Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allied Biotech EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Allied Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Allied Biotech's EV-to-FCF falls into.
Allied Biotech's current Enterprise Value is NT$2,312.0 Mil.
Allied Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$183.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allied Biotech (ROCO:1780) has a EV-to-FCF of 12.60 as of Jul. 19, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Allied Biotech and its competitors. This is 47% below median its historical median of 23.94. Over the past decade, Allied Biotech's EV-to-FCF has ranged from 7.70 to 122.65. According to the industry distribution chart, Allied Biotech ranks #167 out of 565 companies in the Drug Manufacturers industry, placing it in the top 29.6%.
Is Allied Biotech's EV-to-FCF too high?
Allied Biotech's current EV-to-FCF of 12.60 is 47% below median its 10-year median of 23.94. Over the past 10 years, this metric has ranged from a low of 7.70 to a high of 122.65. The Drug Manufacturers industry median EV-to-FCF is 20.96. Allied Biotech's value of 12.60 is 39.9% below this industry median. Based on the distribution chart, Allied Biotech ranks #167 out of 565 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Allied Biotech has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Allied Biotech's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allied Biotech ranks #167 out of 565 companies for EV-to-FCF. This puts Allied Biotech in the upper half of its industry. The industry median EV-to-FCF is 20.96. Allied Biotech's value of 12.60 is 39.9% below this benchmark. Historically, Allied Biotech's own EV-to-FCF has ranged from 7.70 to 122.65 over the past decade. While the company's 10-year median is 23.94 vs. the industry median of 20.96, Allied Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allied Biotech's current EV-to-FCF of 12.60 is 39.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Allied Biotech and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allied Biotech's current EV-to-FCF is 12.60, which is 47% below median its own 10-year median of 23.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allied Biotech stock overvalued right now?
Based on GuruFocus' analysis, Allied Biotech (ROCO:1780) is currently considered Fairly Valued. The stock's GF Value™ is NT$20.77, compared to a current price of NT$22.30 — trading 7.4% above its estimated fair value. The current EV-to-FCF is 12.60, which is 47% below median its 10-year median of 23.94 and 39.9% below the Drug Manufacturers industry median of 20.96. Allied Biotech's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Allied Biotech (ROCO:1780), the current EV-to-FCF is 12.60 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allied Biotech (ROCO:1780) Overvalued in 2026?
Based on GuruFocus' analysis, Allied Biotech stock appears to be overvalued.
The current stock price of NT$22.30 is trading 7.4% above its estimated GF Value™ of NT$20.77.
GuruFocus considers Allied Biotech to be Fairly Valued.
Key valuation signals for ROCO:1780:
EV-to-FCF: 12.60 (47% below median its 10-year median of 23.94)
GF Value™: NT$20.77 vs. price of NT$22.30 (7.4% above fair value)
Industry Position: 39.9% below the Drug Manufacturers median (#167 of 565)
No single metric tells the full story. See the ROCO:1780 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allied Biotech Corp is a Taiwan based manufacturer of carotenoids. It manufactures carotenoid formulations for the food, supplement and feed industries. The company markets its products under the name Altratene.
77GF Score
Get the complete analysis for ROCO:1780
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1780 has been successfully added to your 
